LifeArc

The reinvention of Baxter goes on. The company that in the early 2000s was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in 2025

“There is a lot of capital out there in biotech land that has been largely locked up. Companies are coming through the bottom of the curve in the current funding cycle. The stronger ones have survived

The reinvention of Baxter goes on. The company that in the early “noughties” was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip